Posted by Michael Wonder on 12 Jan 2021
Aerie Pharmaceuticals receives European Commission approval for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
11 January 2021 - Aerie Pharmaceuticals today announced the European Commission has granted a marketing authorisation for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated intra-ocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient intra-ocular pressure reduction.
The marketing authorisation application for Roclanda was accepted for review by the European Medicines Agency in January 2020.
